Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2022

Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,390 recalls, newest first.

Class I · High risk

Morphine Sulfate PF 25 mg/25mL

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Terminated Labeling / mix-up STAQ Pharma, Inc. D-0634-2022
Class I · High risk

HYDROmorphone HCl PF 10 mg/50 mL

Labeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphine Sulfate PF with lot number 21104221A

Terminated Labeling / mix-up STAQ Pharma, Inc. D-0633-2022
Class I · High risk

Hard Dawn

Marketed Without an Approved NDA/ANDA: Firm was informed by Amazon that analytical testing showed the presence of tadalafil. Tadalafil is a FDA approved drug, making this product an unapproved drug.

Terminated Chemical / undeclared Esupplementsales, LLC D-0561-2022
Class II · Moderate risk

Cystex Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. D-0555-2022
Class II · Moderate risk

Back Relief II

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-740-00 D-0551-2022
Class II · Moderate risk

Normed Fem Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-701-00 D-0549-2022
Class II · Moderate risk

APAP 325 mg

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-700-00 D-0548-2022
Class II · Moderate risk

Migrenol Caplet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-565-00 D-0547-2022
Class II · Moderate risk

HPC Tablet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62969-242-00 D-0538-2022

Recalls by year